TLR9 and B-cell non-Hodgkin lymphoma: In their approach, therapeutic targeting of IL-10 in DCs was carried out using siRNAs codelivered with adjuvant CpG (a TLR9 ligand) and a pDNA-antigen (the idiotype protein of A20 B cell lymphoma) associated with a PLGA-PEI (poly[lactic-co-glycolic acid] and polyethylenimine)-derived microparticle [16].